EPIZYME
Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors. Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.
EPIZYME
Industry:
Biopharma Biotechnology Health Care
Founded:
2007-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.epizyme.com
Total Employee:
101+
Status:
Active
Contact:
1(617)349-0707
Email Addresses:
[email protected]
Total Funding:
834.08 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Equity - Epizyme
Royalty Pharma
Royalty Pharma investment in Post-IPO Equity - Epizyme
Celgene
Celgene investment in Post-IPO Equity - Epizyme
GlaxoSmithKline
GlaxoSmithKline investment in Venture Round - Epizyme
Leukemia & Lymphoma Society
Leukemia & Lymphoma Society investment in Venture Round - Epizyme
Multiple Myeloma Research Foundation
Multiple Myeloma Research Foundation investment in Grant - Epizyme
New Enterprise Associates
New Enterprise Associates investment in Series B - Epizyme
Kleiner Perkins
Kleiner Perkins investment in Series B - Epizyme
Astellas Venture Management
Astellas Venture Management investment in Series B - Epizyme
Amgen Ventures
Amgen Ventures investment in Series B - Epizyme
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-15 | Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update |
| 2021-08-09 | Epizyme Announces CEO Succession |
| 2020-03-23 | Epizyme Names Infinity’s Jeffery Kutok as Chief Scientific Officer |
Official Site Inspections
http://www.epizyme.com Semrush global rank: 7.1 M Semrush visits lastest month: 594
- Host name: a4ec4c6ea1c92e2e6.awsglobalaccelerator.com
- IP address: 15.197.142.173
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Epizyme"
Ipsen to acquire Epizyme, expanding its portfolio in oncology
Jun 27, 2022 Transaction focused on lead asset Tazverik ® (tazemetostat), a first-in-class EZH2 a inhibitor approved in the U.S.; Acquisition to bolster Ipsen’s growing oncology presence and …See details»
Epizyme, Inc. Company Profile | Cambridge, MA - Dun & Bradstreet
Company Description: Epizyme is a commercial-stage biopharmaceutical company that is committed to rewriting treatment for people with cancer and other serious diseases through …See details»
Ipsen completes acquisition of Epizyme expanding its portfolio
PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. …See details»
Epizyme Company Profile 2024: Valuation, Investors, Acquisition
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and …See details»
Epizyme Company Profile - Office Locations, Competitors ... - Craft
Aug 4, 2022 Epizyme has 5 employees at their 1 location and $37.43 m in annual revenue in FY 2021. See insights on Epizyme including office locations, competitors, revenue, financials, …See details»
Ipsen completes acquisition of Epizyme expanding its portfolio in …
May 18, 2023 Epizyme now operates as ‘an Ipsen company’ at deal close. As part of the transaction, Ipsen acquires Epizyme’s lead medicine, Tazverik® (tazemetostat), a first-i. News.See details»
Epizyme - Funding, Financials, Valuation & Investors - Crunchbase
Epizyme is registered under the ticker NASDAQ:EPZM . Their stock opened with $15.00 in its May 31, 2013 IPO. Stock Symbol NASDAQ:EPZM ; Valuation at IPO $400M; Money Raised at …See details»
Epizyme Inc - AnnualReports.com
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors …See details»
Epizyme - VentureRadar
" Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel …See details»
Epizyme | EPZM Stock Price, Company Overview
Apr 17, 2020 Leading the group were shares of Epizyme (EPZM), up about 31% and shares of Akebia Therapeutics (AKBA) up about 18.1% on the day. Also showing relative strength are real estate shares, up on the ...See details»
Ipsen - Q1 2022 sales-results presentation - Global
The National Organization for Rare Disorders, Inc. 2021. −Most common indolent non-Hodgkin lymphoma −Composed of malignant cells derived from germinal-center B cells −~15,000 …See details»
Epizyme - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Epizyme . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Profiles 15. Contacts 144. About. Epizyme has 12 current employee …See details»
Epizyme Announces CEO Succession - Business Wire
Aug 9, 2021 Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies toda …See details»
Epizyme Announces CEO Succession - Nasdaq
Aug 9, 2021 Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies today announced its Chief Executive …See details»
Ipsen to acquire Epizyme, expanding its portfolio in oncology
“Epizyme was founded in 2007 with a commitment to rigorous scientific research and a vision of developing novel epigenetic therapies. I am incredibly proud of what our team has …See details»
Epizyme Reports Second Quarter 2022 Financial Results and …
Aug 9, 2022 About Epizyme, Inc. Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through …See details»
Ipsen buys Epizyme for US$247 million - Nature
Jul 6, 2022 Epizyme launched in 2007 to pioneer the development of drugs that can modulate epigenetic drivers of cancer. In 2020, it secured first-in-class accelerated approvals for …See details»
Epizyme Announces Executive Appointment and Provides
Mar 15, 2022 Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. …See details»
Emerging Drug Developer: Epizyme - Fierce Biotech
Epizyme plots a pioneering path in new drug field Two years ago, MPM Capital was hosting a meeting of its scientific advisory board when Yi Zhang, a professor of biochemistry at the …See details»